Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Halozyme Therapeutics, Inc. on May 5, 2022. The filing details the voting results for three proposals presented to shareholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing reports the successful election of three Class III directors and the approval of executive compensation and auditor ratification. There are no material changes to financial conditions or operations disclosed in this specific report.
Guidance, Outlook, and Management Commentary
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly documents the outcomes of shareholder votes.
Important Facts for Investors to Verify
- Shareholder Participation: Of 137,772,750 shares outstanding, 127,251,460 shares were represented at the meeting.
- Director Election Results:
- Jeffrey W. Henderson: Elected with 110,983,960 votes for (approx. 87% of votes cast).
- Connie L. Matsui: Elected with 104,769,877 votes for (approx. 82% of votes cast).
- Helen I. Torley: Elected with 114,703,295 votes for (approx. 90% of votes cast).
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 110,559,045 votes for.
- Auditor Ratification: The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified with 126,668,977 votes for.